nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—Dinoprost Tromethamine—HPGDS—liver cancer	0.0109	0.565	CrCbGaD
Epoprostenol—Dinoprostone—HPGDS—liver cancer	0.00835	0.435	CrCbGaD
Epoprostenol—Epistaxis—Sorafenib—liver cancer	0.00299	0.00671	CcSEcCtD
Epoprostenol—Haemoglobin—Sorafenib—liver cancer	0.00286	0.00642	CcSEcCtD
Epoprostenol—Haemorrhage—Sorafenib—liver cancer	0.00285	0.00639	CcSEcCtD
Epoprostenol—Connective tissue disorder—Sorafenib—liver cancer	0.0028	0.00628	CcSEcCtD
Epoprostenol—Hypercalcaemia—Doxorubicin—liver cancer	0.00279	0.00626	CcSEcCtD
Epoprostenol—Pleural effusion—Epirubicin—liver cancer	0.00274	0.00614	CcSEcCtD
Epoprostenol—Skin ulcer—Epirubicin—liver cancer	0.00269	0.00604	CcSEcCtD
Epoprostenol—Hyperaesthesia—Epirubicin—liver cancer	0.00267	0.00599	CcSEcCtD
Epoprostenol—Cardiac disorder—Sorafenib—liver cancer	0.00264	0.00593	CcSEcCtD
Epoprostenol—Flushing—Sorafenib—liver cancer	0.00264	0.00593	CcSEcCtD
Epoprostenol—Angiopathy—Sorafenib—liver cancer	0.00258	0.00579	CcSEcCtD
Epoprostenol—Injection site pain—Epirubicin—liver cancer	0.00257	0.00576	CcSEcCtD
Epoprostenol—Mediastinal disorder—Sorafenib—liver cancer	0.00256	0.00576	CcSEcCtD
Epoprostenol—Pleural effusion—Doxorubicin—liver cancer	0.00253	0.00568	CcSEcCtD
Epoprostenol—Mental disorder—Sorafenib—liver cancer	0.00249	0.0056	CcSEcCtD
Epoprostenol—Skin ulcer—Doxorubicin—liver cancer	0.00249	0.00559	CcSEcCtD
Epoprostenol—Hyperaesthesia—Doxorubicin—liver cancer	0.00247	0.00554	CcSEcCtD
Epoprostenol—Vasodilation procedure—Epirubicin—liver cancer	0.00238	0.00535	CcSEcCtD
Epoprostenol—Vasodilation—Epirubicin—liver cancer	0.00238	0.00535	CcSEcCtD
Epoprostenol—Muscle spasms—Sorafenib—liver cancer	0.00238	0.00535	CcSEcCtD
Epoprostenol—Injection site pain—Doxorubicin—liver cancer	0.00237	0.00533	CcSEcCtD
Epoprostenol—Rectal haemorrhage—Epirubicin—liver cancer	0.00232	0.0052	CcSEcCtD
Epoprostenol—Cellulitis—Epirubicin—liver cancer	0.0023	0.00517	CcSEcCtD
Epoprostenol—Anaemia—Sorafenib—liver cancer	0.00229	0.00514	CcSEcCtD
Epoprostenol—Syncope—Sorafenib—liver cancer	0.00222	0.00499	CcSEcCtD
Epoprostenol—Vasodilation procedure—Doxorubicin—liver cancer	0.00221	0.00495	CcSEcCtD
Epoprostenol—Vasodilation—Doxorubicin—liver cancer	0.00221	0.00495	CcSEcCtD
Epoprostenol—Loss of consciousness—Sorafenib—liver cancer	0.00218	0.00489	CcSEcCtD
Epoprostenol—Cough—Sorafenib—liver cancer	0.00216	0.00485	CcSEcCtD
Epoprostenol—Rectal haemorrhage—Doxorubicin—liver cancer	0.00215	0.00481	CcSEcCtD
Epoprostenol—Cellulitis—Doxorubicin—liver cancer	0.00213	0.00478	CcSEcCtD
Epoprostenol—Neck pain—Epirubicin—liver cancer	0.00212	0.00476	CcSEcCtD
Epoprostenol—Musculoskeletal pain—Epirubicin—liver cancer	0.00212	0.00476	CcSEcCtD
Epoprostenol—Myalgia—Sorafenib—liver cancer	0.00211	0.00473	CcSEcCtD
Epoprostenol—Arthralgia—Sorafenib—liver cancer	0.00211	0.00473	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00209	0.0047	CcSEcCtD
Epoprostenol—Pulmonary embolism—Epirubicin—liver cancer	0.00209	0.0047	CcSEcCtD
Epoprostenol—Injection site reaction—Epirubicin—liver cancer	0.00208	0.00467	CcSEcCtD
Epoprostenol—Dry mouth—Sorafenib—liver cancer	0.00206	0.00463	CcSEcCtD
Epoprostenol—Hyperkalaemia—Epirubicin—liver cancer	0.00206	0.00462	CcSEcCtD
Epoprostenol—Influenza like illness—Epirubicin—liver cancer	0.00203	0.00456	CcSEcCtD
Epoprostenol—Anaphylactic shock—Sorafenib—liver cancer	0.00202	0.00454	CcSEcCtD
Epoprostenol—Infection—Sorafenib—liver cancer	0.00201	0.00451	CcSEcCtD
Epoprostenol—Shock—Sorafenib—liver cancer	0.00199	0.00446	CcSEcCtD
Epoprostenol—Nervous system disorder—Sorafenib—liver cancer	0.00198	0.00445	CcSEcCtD
Epoprostenol—Thrombocytopenia—Sorafenib—liver cancer	0.00198	0.00444	CcSEcCtD
Epoprostenol—Skin disorder—Sorafenib—liver cancer	0.00196	0.00441	CcSEcCtD
Epoprostenol—Neck pain—Doxorubicin—liver cancer	0.00196	0.0044	CcSEcCtD
Epoprostenol—Musculoskeletal pain—Doxorubicin—liver cancer	0.00196	0.0044	CcSEcCtD
Epoprostenol—Pulmonary embolism—Doxorubicin—liver cancer	0.00194	0.00435	CcSEcCtD
Epoprostenol—Anorexia—Sorafenib—liver cancer	0.00193	0.00433	CcSEcCtD
Epoprostenol—Injection site reaction—Doxorubicin—liver cancer	0.00193	0.00432	CcSEcCtD
Epoprostenol—Cramps of lower extremities—Epirubicin—liver cancer	0.00192	0.00432	CcSEcCtD
Epoprostenol—Hyperkalaemia—Doxorubicin—liver cancer	0.0019	0.00427	CcSEcCtD
Epoprostenol—Influenza like illness—Doxorubicin—liver cancer	0.00188	0.00422	CcSEcCtD
Epoprostenol—Pulmonary oedema—Epirubicin—liver cancer	0.00186	0.00418	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00184	0.00413	CcSEcCtD
Epoprostenol—Sepsis—Epirubicin—liver cancer	0.00182	0.00408	CcSEcCtD
Epoprostenol—Dyspnoea—Sorafenib—liver cancer	0.0018	0.00405	CcSEcCtD
Epoprostenol—Cramps of lower extremities—Doxorubicin—liver cancer	0.00178	0.004	CcSEcCtD
Epoprostenol—Dyspepsia—Sorafenib—liver cancer	0.00178	0.00399	CcSEcCtD
Epoprostenol—Decreased appetite—Sorafenib—liver cancer	0.00176	0.00394	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Sorafenib—liver cancer	0.00175	0.00392	CcSEcCtD
Epoprostenol—Fatigue—Sorafenib—liver cancer	0.00174	0.00391	CcSEcCtD
Epoprostenol—Pain—Sorafenib—liver cancer	0.00173	0.00388	CcSEcCtD
Epoprostenol—Constipation—Sorafenib—liver cancer	0.00173	0.00388	CcSEcCtD
Epoprostenol—Pulmonary oedema—Doxorubicin—liver cancer	0.00172	0.00387	CcSEcCtD
Epoprostenol—Eczema—Epirubicin—liver cancer	0.00169	0.0038	CcSEcCtD
Epoprostenol—Hepatic failure—Epirubicin—liver cancer	0.00169	0.0038	CcSEcCtD
Epoprostenol—Sepsis—Doxorubicin—liver cancer	0.00168	0.00377	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Sorafenib—liver cancer	0.00165	0.00371	CcSEcCtD
Epoprostenol—Urticaria—Sorafenib—liver cancer	0.00161	0.0036	CcSEcCtD
Epoprostenol—Body temperature increased—Sorafenib—liver cancer	0.0016	0.00359	CcSEcCtD
Epoprostenol—Abdominal pain—Sorafenib—liver cancer	0.0016	0.00359	CcSEcCtD
Epoprostenol—Eczema—Doxorubicin—liver cancer	0.00157	0.00351	CcSEcCtD
Epoprostenol—Hepatic failure—Doxorubicin—liver cancer	0.00157	0.00351	CcSEcCtD
Epoprostenol—Cardiac failure—Epirubicin—liver cancer	0.00156	0.0035	CcSEcCtD
Epoprostenol—Hypersensitivity—Sorafenib—liver cancer	0.00149	0.00334	CcSEcCtD
Epoprostenol—Asthenia—Sorafenib—liver cancer	0.00145	0.00326	CcSEcCtD
Epoprostenol—Cardiac failure—Doxorubicin—liver cancer	0.00144	0.00323	CcSEcCtD
Epoprostenol—Pruritus—Sorafenib—liver cancer	0.00143	0.00321	CcSEcCtD
Epoprostenol—Orthostatic hypotension—Epirubicin—liver cancer	0.00139	0.00312	CcSEcCtD
Epoprostenol—Diarrhoea—Sorafenib—liver cancer	0.00138	0.0031	CcSEcCtD
Epoprostenol—Gastritis—Epirubicin—liver cancer	0.00135	0.00302	CcSEcCtD
Epoprostenol—Dizziness—Sorafenib—liver cancer	0.00134	0.003	CcSEcCtD
Epoprostenol—Abdominal distension—Epirubicin—liver cancer	0.00132	0.00297	CcSEcCtD
Epoprostenol—Vomiting—Sorafenib—liver cancer	0.00129	0.00288	CcSEcCtD
Epoprostenol—Orthostatic hypotension—Doxorubicin—liver cancer	0.00128	0.00288	CcSEcCtD
Epoprostenol—Rash—Sorafenib—liver cancer	0.00127	0.00286	CcSEcCtD
Epoprostenol—Dermatitis—Sorafenib—liver cancer	0.00127	0.00286	CcSEcCtD
Epoprostenol—Headache—Sorafenib—liver cancer	0.00127	0.00284	CcSEcCtD
Epoprostenol—Pancytopenia—Epirubicin—liver cancer	0.00125	0.0028	CcSEcCtD
Epoprostenol—Gastritis—Doxorubicin—liver cancer	0.00124	0.00279	CcSEcCtD
Epoprostenol—Abdominal distension—Doxorubicin—liver cancer	0.00122	0.00275	CcSEcCtD
Epoprostenol—Nausea—Sorafenib—liver cancer	0.0012	0.0027	CcSEcCtD
Epoprostenol—Weight decreased—Epirubicin—liver cancer	0.00119	0.00267	CcSEcCtD
Epoprostenol—Pneumonia—Epirubicin—liver cancer	0.00118	0.00264	CcSEcCtD
Epoprostenol—Infestation NOS—Epirubicin—liver cancer	0.00117	0.00263	CcSEcCtD
Epoprostenol—Infestation—Epirubicin—liver cancer	0.00117	0.00263	CcSEcCtD
Epoprostenol—Pancytopenia—Doxorubicin—liver cancer	0.00115	0.00259	CcSEcCtD
Epoprostenol—Urinary tract infection—Epirubicin—liver cancer	0.00114	0.00256	CcSEcCtD
Epoprostenol—Sweating—Epirubicin—liver cancer	0.00112	0.00252	CcSEcCtD
Epoprostenol—Haematuria—Epirubicin—liver cancer	0.00112	0.00251	CcSEcCtD
Epoprostenol—Epistaxis—Epirubicin—liver cancer	0.00111	0.00248	CcSEcCtD
Epoprostenol—Weight decreased—Doxorubicin—liver cancer	0.0011	0.00247	CcSEcCtD
Epoprostenol—Sinusitis—Epirubicin—liver cancer	0.0011	0.00247	CcSEcCtD
Epoprostenol—Pneumonia—Doxorubicin—liver cancer	0.00109	0.00245	CcSEcCtD
Epoprostenol—Infestation NOS—Doxorubicin—liver cancer	0.00108	0.00243	CcSEcCtD
Epoprostenol—Infestation—Doxorubicin—liver cancer	0.00108	0.00243	CcSEcCtD
Epoprostenol—Bradycardia—Epirubicin—liver cancer	0.00107	0.0024	CcSEcCtD
Epoprostenol—Haemoglobin—Epirubicin—liver cancer	0.00106	0.00237	CcSEcCtD
Epoprostenol—Rhinitis—Epirubicin—liver cancer	0.00105	0.00237	CcSEcCtD
Epoprostenol—Urinary tract infection—Doxorubicin—liver cancer	0.00105	0.00236	CcSEcCtD
Epoprostenol—Haemorrhage—Epirubicin—liver cancer	0.00105	0.00236	CcSEcCtD
Epoprostenol—Hypoaesthesia—Epirubicin—liver cancer	0.00105	0.00235	CcSEcCtD
Epoprostenol—Pharyngitis—Epirubicin—liver cancer	0.00104	0.00234	CcSEcCtD
Epoprostenol—Sweating—Doxorubicin—liver cancer	0.00104	0.00233	CcSEcCtD
Epoprostenol—Oedema peripheral—Epirubicin—liver cancer	0.00104	0.00233	CcSEcCtD
Epoprostenol—Haematuria—Doxorubicin—liver cancer	0.00103	0.00232	CcSEcCtD
Epoprostenol—Connective tissue disorder—Epirubicin—liver cancer	0.00103	0.00232	CcSEcCtD
Epoprostenol—Epistaxis—Doxorubicin—liver cancer	0.00102	0.00229	CcSEcCtD
Epoprostenol—Sinusitis—Doxorubicin—liver cancer	0.00102	0.00228	CcSEcCtD
Epoprostenol—Bradycardia—Doxorubicin—liver cancer	0.000991	0.00222	CcSEcCtD
Epoprostenol—Haemoglobin—Doxorubicin—liver cancer	0.000978	0.0022	CcSEcCtD
Epoprostenol—Cardiac disorder—Epirubicin—liver cancer	0.000976	0.00219	CcSEcCtD
Epoprostenol—Flushing—Epirubicin—liver cancer	0.000976	0.00219	CcSEcCtD
Epoprostenol—Rhinitis—Doxorubicin—liver cancer	0.000976	0.00219	CcSEcCtD
Epoprostenol—Haemorrhage—Doxorubicin—liver cancer	0.000973	0.00218	CcSEcCtD
Epoprostenol—Hypoaesthesia—Doxorubicin—liver cancer	0.000968	0.00217	CcSEcCtD
Epoprostenol—Pharyngitis—Doxorubicin—liver cancer	0.000966	0.00217	CcSEcCtD
Epoprostenol—Oedema peripheral—Doxorubicin—liver cancer	0.000959	0.00215	CcSEcCtD
Epoprostenol—Connective tissue disorder—Doxorubicin—liver cancer	0.000956	0.00215	CcSEcCtD
Epoprostenol—Angiopathy—Epirubicin—liver cancer	0.000954	0.00214	CcSEcCtD
Epoprostenol—Mediastinal disorder—Epirubicin—liver cancer	0.000948	0.00213	CcSEcCtD
Epoprostenol—Chills—Epirubicin—liver cancer	0.000944	0.00212	CcSEcCtD
Epoprostenol—Mental disorder—Epirubicin—liver cancer	0.000921	0.00207	CcSEcCtD
Epoprostenol—Flushing—Doxorubicin—liver cancer	0.000903	0.00203	CcSEcCtD
Epoprostenol—Cardiac disorder—Doxorubicin—liver cancer	0.000903	0.00203	CcSEcCtD
Epoprostenol—Flatulence—Epirubicin—liver cancer	0.000902	0.00202	CcSEcCtD
Epoprostenol—Tension—Epirubicin—liver cancer	0.000898	0.00202	CcSEcCtD
Epoprostenol—Nervousness—Epirubicin—liver cancer	0.000889	0.002	CcSEcCtD
Epoprostenol—Back pain—Epirubicin—liver cancer	0.000886	0.00199	CcSEcCtD
Epoprostenol—Angiopathy—Doxorubicin—liver cancer	0.000883	0.00198	CcSEcCtD
Epoprostenol—Muscle spasms—Epirubicin—liver cancer	0.00088	0.00198	CcSEcCtD
Epoprostenol—Mediastinal disorder—Doxorubicin—liver cancer	0.000877	0.00197	CcSEcCtD
Epoprostenol—Chills—Doxorubicin—liver cancer	0.000873	0.00196	CcSEcCtD
Epoprostenol—Mental disorder—Doxorubicin—liver cancer	0.000853	0.00191	CcSEcCtD
Epoprostenol—Anaemia—Epirubicin—liver cancer	0.000846	0.0019	CcSEcCtD
Epoprostenol—Agitation—Epirubicin—liver cancer	0.000841	0.00189	CcSEcCtD
Epoprostenol—Flatulence—Doxorubicin—liver cancer	0.000835	0.00187	CcSEcCtD
Epoprostenol—Tension—Doxorubicin—liver cancer	0.000831	0.00187	CcSEcCtD
Epoprostenol—Nervousness—Doxorubicin—liver cancer	0.000823	0.00185	CcSEcCtD
Epoprostenol—Syncope—Epirubicin—liver cancer	0.000821	0.00184	CcSEcCtD
Epoprostenol—Back pain—Doxorubicin—liver cancer	0.000819	0.00184	CcSEcCtD
Epoprostenol—Muscle spasms—Doxorubicin—liver cancer	0.000815	0.00183	CcSEcCtD
Epoprostenol—Palpitations—Epirubicin—liver cancer	0.000809	0.00182	CcSEcCtD
Epoprostenol—Loss of consciousness—Epirubicin—liver cancer	0.000805	0.00181	CcSEcCtD
Epoprostenol—Cough—Epirubicin—liver cancer	0.000799	0.00179	CcSEcCtD
Epoprostenol—Anaemia—Doxorubicin—liver cancer	0.000783	0.00176	CcSEcCtD
Epoprostenol—Chest pain—Epirubicin—liver cancer	0.000779	0.00175	CcSEcCtD
Epoprostenol—Myalgia—Epirubicin—liver cancer	0.000779	0.00175	CcSEcCtD
Epoprostenol—Arthralgia—Epirubicin—liver cancer	0.000779	0.00175	CcSEcCtD
Epoprostenol—Agitation—Doxorubicin—liver cancer	0.000779	0.00175	CcSEcCtD
Epoprostenol—Anxiety—Epirubicin—liver cancer	0.000777	0.00174	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000774	0.00174	CcSEcCtD
Epoprostenol—Dry mouth—Epirubicin—liver cancer	0.000762	0.00171	CcSEcCtD
Epoprostenol—Syncope—Doxorubicin—liver cancer	0.00076	0.0017	CcSEcCtD
Epoprostenol—Confusional state—Epirubicin—liver cancer	0.000753	0.00169	CcSEcCtD
Epoprostenol—Palpitations—Doxorubicin—liver cancer	0.000749	0.00168	CcSEcCtD
Epoprostenol—Anaphylactic shock—Epirubicin—liver cancer	0.000747	0.00168	CcSEcCtD
Epoprostenol—Oedema—Epirubicin—liver cancer	0.000747	0.00168	CcSEcCtD
Epoprostenol—Loss of consciousness—Doxorubicin—liver cancer	0.000745	0.00167	CcSEcCtD
Epoprostenol—Infection—Epirubicin—liver cancer	0.000742	0.00167	CcSEcCtD
Epoprostenol—Cough—Doxorubicin—liver cancer	0.000739	0.00166	CcSEcCtD
Epoprostenol—Shock—Epirubicin—liver cancer	0.000735	0.00165	CcSEcCtD
Epoprostenol—Nervous system disorder—Epirubicin—liver cancer	0.000733	0.00164	CcSEcCtD
Epoprostenol—Thrombocytopenia—Epirubicin—liver cancer	0.000732	0.00164	CcSEcCtD
Epoprostenol—Tachycardia—Epirubicin—liver cancer	0.000729	0.00164	CcSEcCtD
Epoprostenol—Skin disorder—Epirubicin—liver cancer	0.000726	0.00163	CcSEcCtD
Epoprostenol—Hyperhidrosis—Epirubicin—liver cancer	0.000722	0.00162	CcSEcCtD
Epoprostenol—Myalgia—Doxorubicin—liver cancer	0.000721	0.00162	CcSEcCtD
Epoprostenol—Arthralgia—Doxorubicin—liver cancer	0.000721	0.00162	CcSEcCtD
Epoprostenol—Chest pain—Doxorubicin—liver cancer	0.000721	0.00162	CcSEcCtD
Epoprostenol—Anxiety—Doxorubicin—liver cancer	0.000719	0.00161	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000716	0.00161	CcSEcCtD
Epoprostenol—Anorexia—Epirubicin—liver cancer	0.000712	0.0016	CcSEcCtD
Epoprostenol—Dry mouth—Doxorubicin—liver cancer	0.000705	0.00158	CcSEcCtD
Epoprostenol—Hypotension—Epirubicin—liver cancer	0.000698	0.00157	CcSEcCtD
Epoprostenol—Confusional state—Doxorubicin—liver cancer	0.000697	0.00156	CcSEcCtD
Epoprostenol—Oedema—Doxorubicin—liver cancer	0.000691	0.00155	CcSEcCtD
Epoprostenol—Anaphylactic shock—Doxorubicin—liver cancer	0.000691	0.00155	CcSEcCtD
Epoprostenol—Infection—Doxorubicin—liver cancer	0.000687	0.00154	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000681	0.00153	CcSEcCtD
Epoprostenol—Shock—Doxorubicin—liver cancer	0.00068	0.00153	CcSEcCtD
Epoprostenol—Nervous system disorder—Doxorubicin—liver cancer	0.000678	0.00152	CcSEcCtD
Epoprostenol—Thrombocytopenia—Doxorubicin—liver cancer	0.000677	0.00152	CcSEcCtD
Epoprostenol—Insomnia—Epirubicin—liver cancer	0.000676	0.00152	CcSEcCtD
Epoprostenol—Tachycardia—Doxorubicin—liver cancer	0.000675	0.00151	CcSEcCtD
Epoprostenol—Skin disorder—Doxorubicin—liver cancer	0.000672	0.00151	CcSEcCtD
Epoprostenol—Paraesthesia—Epirubicin—liver cancer	0.000671	0.00151	CcSEcCtD
Epoprostenol—Hyperhidrosis—Doxorubicin—liver cancer	0.000668	0.0015	CcSEcCtD
Epoprostenol—Dyspnoea—Epirubicin—liver cancer	0.000666	0.0015	CcSEcCtD
Epoprostenol—Somnolence—Epirubicin—liver cancer	0.000664	0.00149	CcSEcCtD
Epoprostenol—Anorexia—Doxorubicin—liver cancer	0.000659	0.00148	CcSEcCtD
Epoprostenol—Dyspepsia—Epirubicin—liver cancer	0.000658	0.00148	CcSEcCtD
Epoprostenol—Decreased appetite—Epirubicin—liver cancer	0.00065	0.00146	CcSEcCtD
Epoprostenol—Hypotension—Doxorubicin—liver cancer	0.000646	0.00145	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Epirubicin—liver cancer	0.000645	0.00145	CcSEcCtD
Epoprostenol—Fatigue—Epirubicin—liver cancer	0.000644	0.00145	CcSEcCtD
Epoprostenol—Constipation—Epirubicin—liver cancer	0.000639	0.00143	CcSEcCtD
Epoprostenol—Pain—Epirubicin—liver cancer	0.000639	0.00143	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00063	0.00141	CcSEcCtD
Epoprostenol—Insomnia—Doxorubicin—liver cancer	0.000625	0.0014	CcSEcCtD
Epoprostenol—Paraesthesia—Doxorubicin—liver cancer	0.000621	0.00139	CcSEcCtD
Epoprostenol—Dyspnoea—Doxorubicin—liver cancer	0.000616	0.00138	CcSEcCtD
Epoprostenol—Somnolence—Doxorubicin—liver cancer	0.000615	0.00138	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Epirubicin—liver cancer	0.000611	0.00137	CcSEcCtD
Epoprostenol—Dyspepsia—Doxorubicin—liver cancer	0.000609	0.00137	CcSEcCtD
Epoprostenol—Decreased appetite—Doxorubicin—liver cancer	0.000601	0.00135	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000597	0.00134	CcSEcCtD
Epoprostenol—Fatigue—Doxorubicin—liver cancer	0.000596	0.00134	CcSEcCtD
Epoprostenol—Urticaria—Epirubicin—liver cancer	0.000594	0.00133	CcSEcCtD
Epoprostenol—Pain—Doxorubicin—liver cancer	0.000591	0.00133	CcSEcCtD
Epoprostenol—Constipation—Doxorubicin—liver cancer	0.000591	0.00133	CcSEcCtD
Epoprostenol—Abdominal pain—Epirubicin—liver cancer	0.000591	0.00133	CcSEcCtD
Epoprostenol—Body temperature increased—Epirubicin—liver cancer	0.000591	0.00133	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Doxorubicin—liver cancer	0.000565	0.00127	CcSEcCtD
Epoprostenol—Hypersensitivity—Epirubicin—liver cancer	0.000551	0.00124	CcSEcCtD
Epoprostenol—Urticaria—Doxorubicin—liver cancer	0.000549	0.00123	CcSEcCtD
Epoprostenol—Abdominal pain—Doxorubicin—liver cancer	0.000547	0.00123	CcSEcCtD
Epoprostenol—Body temperature increased—Doxorubicin—liver cancer	0.000547	0.00123	CcSEcCtD
Epoprostenol—Asthenia—Epirubicin—liver cancer	0.000536	0.0012	CcSEcCtD
Epoprostenol—Pruritus—Epirubicin—liver cancer	0.000529	0.00119	CcSEcCtD
Epoprostenol—Diarrhoea—Epirubicin—liver cancer	0.000511	0.00115	CcSEcCtD
Epoprostenol—Hypersensitivity—Doxorubicin—liver cancer	0.000509	0.00114	CcSEcCtD
Epoprostenol—Asthenia—Doxorubicin—liver cancer	0.000496	0.00111	CcSEcCtD
Epoprostenol—Dizziness—Epirubicin—liver cancer	0.000494	0.00111	CcSEcCtD
Epoprostenol—Pruritus—Doxorubicin—liver cancer	0.000489	0.0011	CcSEcCtD
Epoprostenol—Vomiting—Epirubicin—liver cancer	0.000475	0.00107	CcSEcCtD
Epoprostenol—Diarrhoea—Doxorubicin—liver cancer	0.000473	0.00106	CcSEcCtD
Epoprostenol—Rash—Epirubicin—liver cancer	0.000471	0.00106	CcSEcCtD
Epoprostenol—Dermatitis—Epirubicin—liver cancer	0.000471	0.00106	CcSEcCtD
Epoprostenol—Headache—Epirubicin—liver cancer	0.000468	0.00105	CcSEcCtD
Epoprostenol—Dizziness—Doxorubicin—liver cancer	0.000457	0.00103	CcSEcCtD
Epoprostenol—Nausea—Epirubicin—liver cancer	0.000444	0.000996	CcSEcCtD
Epoprostenol—Vomiting—Doxorubicin—liver cancer	0.00044	0.000987	CcSEcCtD
Epoprostenol—Rash—Doxorubicin—liver cancer	0.000436	0.000978	CcSEcCtD
Epoprostenol—Dermatitis—Doxorubicin—liver cancer	0.000436	0.000977	CcSEcCtD
Epoprostenol—Headache—Doxorubicin—liver cancer	0.000433	0.000972	CcSEcCtD
Epoprostenol—Nausea—Doxorubicin—liver cancer	0.000411	0.000922	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—MTHFR—liver cancer	0.00021	0.000393	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—CYP1A1—liver cancer	0.00021	0.000393	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PSMD10—liver cancer	0.00021	0.000393	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PSMA4—liver cancer	0.00021	0.000393	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PSMD10—liver cancer	0.00021	0.000393	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PSMA4—liver cancer	0.00021	0.000393	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.000209	0.000391	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—F2—liver cancer	0.000208	0.000389	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—VEGFA—liver cancer	0.000207	0.000388	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PPARA—liver cancer	0.000206	0.000386	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CG—liver cancer	0.000202	0.000377	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CG—liver cancer	0.000202	0.000377	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CG—liver cancer	0.000199	0.000372	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—BRAF—liver cancer	0.000198	0.000371	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PIK3CD—liver cancer	0.000193	0.00036	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—F2—liver cancer	0.000191	0.000358	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—F2—liver cancer	0.000191	0.000358	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—VEGFA—liver cancer	0.000191	0.000357	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TGFB1—liver cancer	0.00019	0.000356	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PIK3CD—liver cancer	0.000186	0.000347	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	0.000185	0.000346	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—SERPINE1—liver cancer	0.000184	0.000343	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CG—liver cancer	0.000183	0.000342	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CG—liver cancer	0.000183	0.000342	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CD—liver cancer	0.000177	0.000331	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CD—liver cancer	0.000177	0.000331	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PRKCE—liver cancer	0.000177	0.000331	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CG—liver cancer	0.000177	0.00033	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—KRAS—liver cancer	0.000176	0.000329	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TGFB1—liver cancer	0.000175	0.000327	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CD—liver cancer	0.000175	0.000327	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PPARG—liver cancer	0.000171	0.000319	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PIK3CB—liver cancer	0.000168	0.000314	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IGF2—liver cancer	0.000168	0.000313	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—RAF1—liver cancer	0.000166	0.00031	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PRKCE—liver cancer	0.000163	0.000304	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PRKCE—liver cancer	0.000163	0.000304	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—KRAS—liver cancer	0.000162	0.000303	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—PIK3CA—liver cancer	0.000162	0.000303	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MTOR—liver cancer	0.000162	0.000302	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PIK3CB—liver cancer	0.000162	0.000302	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CD—liver cancer	0.000161	0.000301	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CD—liver cancer	0.000161	0.000301	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.00016	0.000299	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—UGDH—liver cancer	0.00016	0.000298	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TP53—liver cancer	0.000157	0.000293	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CSF2—liver cancer	0.000157	0.000293	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—RAF1—liver cancer	0.000156	0.000292	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CD—liver cancer	0.000155	0.00029	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CB—liver cancer	0.000155	0.000289	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CB—liver cancer	0.000155	0.000289	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—H2AFX—liver cancer	0.000154	0.000288	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IGF2—liver cancer	0.000154	0.000288	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IGF2—liver cancer	0.000154	0.000288	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—IL2—liver cancer	0.000154	0.000288	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—ALB—liver cancer	0.000153	0.000287	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CB—liver cancer	0.000152	0.000285	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CDKN1B—liver cancer	0.000152	0.000284	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—EPT1—liver cancer	0.00015	0.00028	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—HRAS—liver cancer	0.00015	0.00028	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—PIK3CA—liver cancer	0.000149	0.000279	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TP53—liver cancer	0.000144	0.000269	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CSF2—liver cancer	0.000144	0.000269	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CSF2—liver cancer	0.000144	0.000269	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—RAF1—liver cancer	0.000144	0.000269	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—RAF1—liver cancer	0.000144	0.000269	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CTNNB1—liver cancer	0.000143	0.000268	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TAT—liver cancer	0.000142	0.000266	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—H2AFX—liver cancer	0.000142	0.000265	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—H2AFX—liver cancer	0.000142	0.000265	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—IL2—liver cancer	0.000142	0.000265	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—IL2—liver cancer	0.000142	0.000265	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CB—liver cancer	0.00014	0.000262	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CB—liver cancer	0.00014	0.000262	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CDKN1A—liver cancer	0.00014	0.000262	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL2—liver cancer	0.00014	0.000262	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.00014	0.000261	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TERT—liver cancer	0.00014	0.000261	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—HRAS—liver cancer	0.000138	0.000258	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CB—liver cancer	0.000135	0.000253	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—AKT1—liver cancer	0.000132	0.000247	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL2—liver cancer	0.000129	0.000241	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL2—liver cancer	0.000129	0.000241	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TERT—liver cancer	0.000128	0.00024	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TERT—liver cancer	0.000128	0.00024	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KDR—liver cancer	0.000128	0.000238	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MAPK14—liver cancer	0.000127	0.000237	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—STAT3—liver cancer	0.000125	0.000234	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ESR1—liver cancer	0.000124	0.000232	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—F2—liver cancer	0.000123	0.00023	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—AKT1—liver cancer	0.000122	0.000228	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—APC—liver cancer	0.000118	0.00022	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CG—liver cancer	0.000118	0.00022	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KDR—liver cancer	0.000117	0.000219	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KDR—liver cancer	0.000117	0.000219	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MAPK14—liver cancer	0.000117	0.000218	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MAPK14—liver cancer	0.000117	0.000218	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MYC—liver cancer	0.000116	0.000217	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—TGFB1—liver cancer	0.000116	0.000217	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ESR1—liver cancer	0.000114	0.000214	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ESR1—liver cancer	0.000114	0.000214	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—F2—liver cancer	0.000113	0.000211	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—F2—liver cancer	0.000113	0.000211	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—BRAF—liver cancer	0.000111	0.000206	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—APC—liver cancer	0.000108	0.000202	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CG—liver cancer	0.000108	0.000202	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—APC—liver cancer	0.000108	0.000202	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CG—liver cancer	0.000108	0.000202	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—KRAS—liver cancer	0.000107	0.000201	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—liver cancer	0.000105	0.000196	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CD—liver cancer	0.000103	0.000193	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PIK3CA—liver cancer	0.000102	0.000191	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SERPINE1—liver cancer	0.000102	0.000191	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—BRAF—liver cancer	0.000102	0.00019	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—BRAF—liver cancer	0.000102	0.00019	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—KRAS—liver cancer	0.000101	0.000189	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PIK3CA—liver cancer	9.86e-05	0.000184	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CPT1B—liver cancer	9.66e-05	0.000181	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GLUL—liver cancer	9.66e-05	0.000181	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CD—liver cancer	9.51e-05	0.000178	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CD—liver cancer	9.51e-05	0.000178	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CA—liver cancer	9.42e-05	0.000176	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CA—liver cancer	9.42e-05	0.000176	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SERPINE1—liver cancer	9.41e-05	0.000176	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SERPINE1—liver cancer	9.41e-05	0.000176	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NR1H4—liver cancer	9.32e-05	0.000174	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—KRAS—liver cancer	9.31e-05	0.000174	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—KRAS—liver cancer	9.31e-05	0.000174	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CA—liver cancer	9.3e-05	0.000174	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—RAF1—liver cancer	9.23e-05	0.000172	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTA3—liver cancer	9.16e-05	0.000171	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—HRAS—liver cancer	9.12e-05	0.00017	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MTOR—liver cancer	9.01e-05	0.000168	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CB—liver cancer	9.01e-05	0.000168	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—IL6—liver cancer	8.73e-05	0.000163	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—HRAS—liver cancer	8.6e-05	0.000161	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CA—liver cancer	8.56e-05	0.00016	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CA—liver cancer	8.56e-05	0.00016	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—RAF1—liver cancer	8.49e-05	0.000159	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—RAF1—liver cancer	8.49e-05	0.000159	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CDKN1B—liver cancer	8.45e-05	0.000158	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTA4—liver cancer	8.38e-05	0.000157	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—AKT1—liver cancer	8.36e-05	0.000156	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MTOR—liver cancer	8.29e-05	0.000155	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CB—liver cancer	8.29e-05	0.000155	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MTOR—liver cancer	8.29e-05	0.000155	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CB—liver cancer	8.29e-05	0.000155	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CASP3—liver cancer	8.29e-05	0.000155	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL2—liver cancer	8.27e-05	0.000155	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CA—liver cancer	8.26e-05	0.000154	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL6—liver cancer	8.23e-05	0.000154	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	8.19e-05	0.000153	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTA2—liver cancer	8.17e-05	0.000153	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCND1—liver cancer	8.06e-05	0.000151	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—AKT1—liver cancer	8.06e-05	0.000151	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—JUN—liver cancer	8.05e-05	0.00015	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CTNNB1—liver cancer	7.99e-05	0.000149	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—HRAS—liver cancer	7.92e-05	0.000148	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—HRAS—liver cancer	7.92e-05	0.000148	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTA1—liver cancer	7.88e-05	0.000147	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MMP9—liver cancer	7.83e-05	0.000146	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CDKN1A—liver cancer	7.8e-05	0.000146	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NAT2—liver cancer	7.79e-05	0.000146	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CDKN1B—liver cancer	7.78e-05	0.000145	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CDKN1B—liver cancer	7.78e-05	0.000145	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—AKT1—liver cancer	7.7e-05	0.000144	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—AKT1—liver cancer	7.7e-05	0.000144	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CASP3—liver cancer	7.63e-05	0.000142	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CASP3—liver cancer	7.63e-05	0.000142	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MAPK8—liver cancer	7.62e-05	0.000142	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL2—liver cancer	7.61e-05	0.000142	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL2—liver cancer	7.61e-05	0.000142	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—AKT1—liver cancer	7.59e-05	0.000142	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL6—liver cancer	7.58e-05	0.000142	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL6—liver cancer	7.58e-05	0.000142	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	7.49e-05	0.00014	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALDOB—liver cancer	7.47e-05	0.00014	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCND1—liver cancer	7.42e-05	0.000139	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCND1—liver cancer	7.42e-05	0.000139	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—JUN—liver cancer	7.41e-05	0.000138	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—JUN—liver cancer	7.41e-05	0.000138	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CTNNB1—liver cancer	7.35e-05	0.000137	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CTNNB1—liver cancer	7.35e-05	0.000137	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MMP9—liver cancer	7.21e-05	0.000135	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MMP9—liver cancer	7.21e-05	0.000135	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CDKN1A—liver cancer	7.18e-05	0.000134	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CDKN1A—liver cancer	7.18e-05	0.000134	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CRABP1—liver cancer	7.12e-05	0.000133	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—VEGFA—liver cancer	7.03e-05	0.000131	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MAPK8—liver cancer	7.01e-05	0.000131	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MAPK8—liver cancer	7.01e-05	0.000131	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—AKT1—liver cancer	6.99e-05	0.000131	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—AKT1—liver cancer	6.99e-05	0.000131	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—STAT3—liver cancer	6.96e-05	0.00013	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—AKT1—liver cancer	6.75e-05	0.000126	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—VEGFA—liver cancer	6.47e-05	0.000121	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—VEGFA—liver cancer	6.47e-05	0.000121	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MYC—liver cancer	6.47e-05	0.000121	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TGFB1—liver cancer	6.45e-05	0.000121	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	6.41e-05	0.00012	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—STAT3—liver cancer	6.41e-05	0.00012	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—STAT3—liver cancer	6.41e-05	0.00012	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HPGDS—liver cancer	6.23e-05	0.000116	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	6.19e-05	0.000116	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KRAS—liver cancer	5.98e-05	0.000112	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MYC—liver cancer	5.95e-05	0.000111	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MYC—liver cancer	5.95e-05	0.000111	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TGFB1—liver cancer	5.94e-05	0.000111	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TGFB1—liver cancer	5.94e-05	0.000111	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	5.64e-05	0.000105	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	5.57e-05	0.000104	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PSMD10—liver cancer	5.55e-05	0.000104	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PSMA4—liver cancer	5.55e-05	0.000104	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KRAS—liver cancer	5.5e-05	0.000103	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KRAS—liver cancer	5.5e-05	0.000103	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CA—liver cancer	5.49e-05	0.000103	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GOT2—liver cancer	5.4e-05	0.000101	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TP53—liver cancer	5.31e-05	9.93e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HRAS—liver cancer	5.08e-05	9.49e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP2E1—liver cancer	5.08e-05	9.49e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CA—liver cancer	5.05e-05	9.44e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CA—liver cancer	5.05e-05	9.44e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	4.92e-05	9.18e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TP53—liver cancer	4.89e-05	9.14e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TP53—liver cancer	4.89e-05	9.14e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL6—liver cancer	4.86e-05	9.09e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYCS—liver cancer	4.75e-05	8.87e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HRAS—liver cancer	4.68e-05	8.74e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HRAS—liver cancer	4.68e-05	8.74e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GGT1—liver cancer	4.66e-05	8.71e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GOT1—liver cancer	4.66e-05	8.71e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AKT1—liver cancer	4.49e-05	8.38e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL6—liver cancer	4.48e-05	8.36e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL6—liver cancer	4.48e-05	8.36e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTP1—liver cancer	4.19e-05	7.82e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HMOX1—liver cancer	4.13e-05	7.71e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AKT1—liver cancer	4.13e-05	7.71e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AKT1—liver cancer	4.13e-05	7.71e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTM1—liver cancer	3.85e-05	7.19e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP1A1—liver cancer	3.65e-05	6.81e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MTHFR—liver cancer	3.4e-05	6.35e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPARA—liver cancer	3.34e-05	6.23e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3e-05	5.6e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CG—liver cancer	2.86e-05	5.34e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPARG—liver cancer	2.76e-05	5.15e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CD—liver cancer	2.51e-05	4.69e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALB—liver cancer	2.48e-05	4.63e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CB—liver cancer	2.19e-05	4.09e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CA—liver cancer	1.33e-05	2.49e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AKT1—liver cancer	1.09e-05	2.04e-05	CbGpPWpGaD
